STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction - A protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Ganzevoort, Wessel ^a   Alfirevic, Zarko ^b   von Dadelszen, Peter ^c   Kenny, Louise ^d   Papageorghiou, Aris ^e   van Wassenaer Leemhuis, Aleid ^a   Gluud, Christian ^f   Mol, Ben Willem ^a   Baker, Philip N ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f University of Copenhagen   (Denmark)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adverse neonatal outcome; Fetal growth restriction; Individual participant data meta analysis; Sildenafil

Indexed keywords

PLACENTAL GROWTH FACTOR; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ABDOMINAL CIRCUMFERENCE; BIRTH WEIGHT; BLOOD FLOW; COGNITION; CONGENITAL MALFORMATION; DISEASE SEVERITY; FETUS GROWTH; FETUS WEIGHT; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LUNG DYSPLASIA; META ANALYSIS; MOTOR DEVELOPMENT; NECROTIZING ENTEROCOLITIS; NERVOUS SYSTEM INJURY; PREECLAMPSIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; FEMALE; PREGNANCY;

FEMALE; FETAL GROWTH RETARDATION; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PREGNANCY; PURINES; SULFONES;

EID: 84907262864     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-23     Document Type: Review

References (33)

1. Lee MJ, Conner EL, Charafeddine L, Woods JR, Del Priore G. A critical birth weight and other determinants of survival for infants with severe intrauterine growth restriction. Ann N Y Acad Sci 2001, 943:326-339.
2. Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006, 195(6):1557-1563. 10.1016/j.ajog.2006.05.021, 17014813.
3. Petersen SG, Wong SF, Urs P, Gray PH, Gardener GJ. Early onset, severe fetal growth restriction with absent or reversed end-diastolic flow velocity waveform in the umbilical artery: perinatal and long-term outcomes. Aust N Z J Obstet Gynaecol 2009, 49(1):45-51. 10.1111/j.1479-828X.2008.00938.x, 19281579.
4. Batton DG, DeWitte DB, Espinosa R, Swails TL. The impact of fetal compromise on outcome at the border of viability. Am J Obstet Gynecol 1998, 178(5):909-915. 10.1016/S0002-9378(98)70522-8, 9609558.
5. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med 2000, 343(6):378-384.
6. Larroque B, Ancel PY, Marchand-Martin L, Cambonie G, Fresson J, Pierrat V, Rozé JC, Marpeau L, Thiriez G, Alberge C, Bréart G, Kaminski M, Marret S, . Epipage Study group Special care and school difficulties in 8-year-old very preterm children: the Epipage cohort study. PLoS One 2011, 6(7):e21361. 10.1371/journal.pone.0021361, 3132214, 21760892, Epipage Study group.
7. Ganzevoort W, Rep A, De Vries JI, Bonsel GJ, Wolf H, . PETRA-investigators Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006, 195(2):495-503. 10.1016/j.ajog.2006.02.012, 16643825, PETRA-investigators.
8. Guellec I, Lapillonne A, Renolleau S, Charlaluk ML, Roze JC, Marret S, Vieux R, Monique K, Ancel PY, . EPIPAGE Study Group Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction. Pediatrics 2011, 127(4):e883-e891. 10.1542/peds.2010-2442, 21382951, EPIPAGE Study Group.
9. Walther FJ, Den Ouden AL, Verloove-Vanhorick SP. Looking back in time: outcome of a national cohort of very preterm infants born in The Netherlands in 1983. Early Hum Dev 2000, 59(3):175-191. 10.1016/S0378-3782(00)00094-3, 10996273.
10. Stanley JL, Andersson IJ, Poudel R, Rueda-Clausen CF, Sibley CP, Davidge ST, Baker PN. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension 2012, 59(5):1021-1028. 10.1161/HYPERTENSIONAHA.111.186270, 22392899.
11. Wareing M, Myers JE, O'Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005, 90(5):2550-2555. 10.1210/jc.2004-1831, 15713717.
12. Herraiz S, Pellicer B, Serra V, Cauli O, Cortijo J, Felipo V, Pellicer A. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG 2012, 119(11):1394-1402. 10.1111/j.1471-0528.2012.03430.x, 22827567.
13. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009, 28(4):369-382. 10.3109/10641950802601278, 19843000.
14. von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, . Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG 2011, 118(5):624-628. 10.1111/j.1471-0528.2010.02879.x, 21392225, Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group.
15. GONet. Available from: http://www.globalobstetricsnetwork.org.
16. Broeze KA, Opmeer BC, van der Veen F, Bossuyt PM, Bhattacharya S, Mol BW. Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine. Hum Reprod Update 2010, 16(6):561-567. 10.1093/humupd/dmq043, 20819831.
17. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008, 61(1):64-75. 10.1016/j.jclinepi.2007.03.013, 18083463.
18. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int J Epidemiol 2009, 38(1):276-286. 10.1093/ije/dyn179, 18824467.
19. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, Guyatt G, Devereaux PJ, Thabane L. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis-a simulation study. PLoS One 2011, 6(10):e25491. 10.1371/journal.pone.0025491, 3196500, 22028777.
20. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009, 9:86. 10.1186/1471-2288-9-86, 2809074, 20042080.
21. User Manual for Trial Sequential Analysis (TSA) from the Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark. http://www.ctu.dk/tsa/.
22. WHO Trial Portal. http://apps.who.int/trialsearch/.
23. Current Controlled Trials. http://www.controlled-trials.com.
24. The Australian and New Zealand Trials Register. http://www.anzctr.org.au.
25. ISRCTN Register. http://www.isrctn.org.
26. The Cochrane Handbook for Systematic Reviews of Interventions. http://www.cochrane.org/training/cochrane-handbook.
27. Savovic J, Jones H, Altman D, Harris R, Juni P, Pildal J, Als-Nielsen B, Balk E, Gluud C, Gluud L, Ioannidis J, Schulz K, Beynon R, Welton N, Wood L, Moher D, Deeks J, Sterne J. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012, 16(35):1-82.
28. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012, 157(6):429-438. 10.7326/0003-4819-157-6-201209180-00537, 22945832.
29. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008, 336(7644):601-605. 10.1136/bmj.39465.451748.AD, 2267990, 18316340.
30. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012, 12. MR000033.
31. Jakobsen JCGC. The necessity of randomized clinical trials. Br J Med Med Res 2013, 3(4):16.
32. Grade Working Group. http://www.gradeworkinggroup.org.
33. Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol 2010, 10:90. 10.1186/1471-2288-10-90, 2959031, 20920306.